Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea-Reference-Cited by-同舟云学术

Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea

Published:2015-02 Issue:2 Volume:87 Page:148-154
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Baek Jin Ho,Sun Jong-Mu,Min Young Joo,Cho Eun Kyung,Cho Byoung Chul,Kim Joo-Hang,Ahn Myung-Ju,Park Keunchil

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. Cancer statistics;Jemal;CA Cancer J Clin,2007

2. Fifty years of cancer incidence: CI5 I-IX;Parkin;Int J Cancer,2010

3. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel;Gridelli;J Clin Oncol,2005

4. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

5. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis;Cellular Oncology;2024-06-18

2. The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects;Investigational New Drugs;2024-04-11

3. Single-cell mass spectrometry studies of drug metabolism heterogeneity and primary resistance to gefitinib in non-small cell lung cancer cells;Chinese Chemical Letters;2024-02

4. Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study;BMC Cancer;2023-10-16

5. The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib;Translational Cancer Research;2023-08